An international study published recently in the Journal of General Internal Medicine (online ahead of print) found that pharmaceutical sales representatives rarely mentioned serious adverse events when pitching medications to physicians.

The researchers said this “raises questions about whether current approaches to regulation of sales representatives adequately protect patient health.” The study included 255 primary care physicians who reported on 1,692 drug-specific promotions.

Renal & Urology News would like to know what urologists’ and nephrologists’ experience has been in this regard, so please answer the following poll question.

Continue Reading